Sara Tolaney, MD, MPH, Dana-Farber Cancer Institute, Boston, MA, provides insights and expertise on the management of HR+, HER2-negative early breast cancer, touching on novel agents including abemaciclib, an oral CDK4/6 inhibitor which has resulted in improvement in invasive disease-free survival as well as new challenges, such as a potential benefit for intermediate-risk patients, duration of treatment as well as the potential for the omission of chemotherapy. This interview took place at the St. Gallen International Breast Cancer Consensus Meeting in Vienna, Austria.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
